The FDA imposed a clinical hold on five studies testing Gilead’s investigational long-acting HIV pill combination GS-1720 and GS-4182 following immune cell count declines in some participants. This pause raises concerns about potential immune system compromise and delays in development of new treatment options for HIV patients.